Drug Profile
Research programme: recombinant human alpha-1 antitrypsin - rEVO Biologics
Alternative Names: AAT - GTC; Alpha-1 proteinase inhibitor - GTC; Alpha-1-antitrypsin - GTC; rhAAT - GTC; TgAAT - GTCLatest Information Update: 25 Sep 2021
Price :
$50
*
At a glance
- Originator GTC Biotherapeutics; LFB Biotechnologies
- Developer rEVO Biologics
- Class Acute-phase proteins; Alpha globulins; Anti-inflammatories; Antiallergics; Antihyperglycaemics; Blood proteins; Secretory proteinase inhibitory proteins; Serpins
- Mechanism of Action Pancreatic elastase inhibitors; Serine endopeptidase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- Available For Licensing Yes - Alpha 1-antitrypsin deficiency
Highest Development Phases
- No development reported Alpha 1-antitrypsin deficiency
Most Recent Events
- 04 Nov 2017 No recent reports of development identified for preclinical development in Alpha-1-antitrypsin-deficiency in France (Parenteral)
- 04 Nov 2017 No recent reports of development identified for preclinical development in Alpha-1-antitrypsin-deficiency in USA (Parenteral)
- 04 Jan 2013 GTC Biotherapeutics is now called rEVO Biologics